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      Dear  Sir: 
  We note with interest Rolim and colleagues’ cross-sectional 
serosurvey of residents of Tejuçuoca and Banabuiu in Ceará, 
Brazil to provide evidence of exposure to   Burkholderia 
pseudomallei  , the causative agent of melioidosis.  1   Although 
there is definitive evidence of culture-confirmed melioidosis 
in that region,  2   we caution against the use of an unvalidated 
enzyme-linked immunosorbent assay (ELISA) such as that 
used by Rolim and others to provide evidence of widespread 
exposure. 
  Although all serological tests are of relatively limited value 
for the diagnosis of melioidosis in patients living in areas where 
melioidosis is endemic (primarily because of seropositivity in 
the healthy population), the indirect hemagglutination assay 
(IHA) is widely accepted as the serological test of choice. The 
diagnostic performance of the IHA has been defined by sev-
eral studies that used different cutoffs to take account of vari-
able rates of background seropositivity. In the endemic region 
of Australia, the diagnostic sensitivity of an IHA titer of ≥ 1:40 
was 56% at the time of admission (using culture as the gold 
standard), with evidence of subsequent seroconversion on 
serial IHA testing in 68% of patients who were initially IHA 
negative.  3   In northeast Thailand, the diagnostic sensitivity of 
the much higher IHA titer of ≥ 1:160 was 72% and the speci-
ficity 64%.  4   Other assays have been evaluated but have only 
been found to offer a marginal improvement on the IHA.  5  
  Although the true incidence of culture-confirmed melioi-
dosis in this region of Brazil is not known, the proportion of 
residents with positive serology in this study, reported as 58%, 
seems very high compared with known endemic areas where 
the incidence of confirmed melioidosis is known to be high. 
The sensitivity and specificity of the assay used by Rolim and 
others for indicating exposure to   B. pseudomallei   appears  to 
be unknown from the data presented. One possible explana-
tion for the high seropositivity observed is the use of an inap-
propriately low cutoff. We note that Rolim and colleagues also 
performed the ELISA used in their study on 20 serum samples 
from Australia that were negative by IHA, but were clinically 
uncharacterized, as was the negative control used in the test. 
Three of these samples were positive for immunoglobulin G 
(IgG) in their ELISA, of which one was also positive for IgM, 
suggesting a specificity for IgG of 85% (95% confidence inter-
val [CI]: 62%, 97%) compared with IHA. A cut-off value was 
described as being the mean of the optical densities of a nega-
tive control. If the optical densities are normally distributed, 
it would then be expected that half the results from a nega-
tive control would be interpreted as positive. Another possible 
explanation for the high seropositivity observed is exposure 
to cross-reacting antigens in another environmental organism 
analogous to avirulent   Burkholderia thailandensis   as found in 
SE Asia. 
  We have previously raised concerns that apparently unvali-
dated assays are being used to provide evidence of exposure 
in other settings.  6   Current recommendations for laboratory 
workers with exposure to   B. pseudomallei   suggest that base-
line and post-exposure serology should be used for accurate 
interpretation of seropositivity after a potential exposure 
event, but the recommendations caution that a validated assay 
such as the IHA should be used.  7   We have become aware that 
probable false positive results are occurring from at least one 
unvalidated serological assay, resulting in unnecessary anxi-
ety in some laboratory workers with no evident exposure 
event. 
  We call for studies to develop and validate the use of a 
serological standard to assess exposure to   B. pseudomallei . 
Ideally, such an assay should be accurate, inexpensive, simple 
to perform, and be reproducible between laboratories. In the 
interim, serological evidence of exposure should be based on 
assays with known sensitivity and specificity against culture-
confirmed melioidosis. 
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